Cellular Biomedicine Group, Inc. (CBMG): Wei (william) Cao , director of Cellular Biomedicine Group, Inc. sold 10,000 shares on Mar 1, 2016. The Insider selling transaction was reported by the company on Apr 14, 2016 to the Securities and Exchange Commission. The shares were sold at $17.15 per share for a total value of $171,500.00 according the SEC Form 4 Filing.
Currently the company Insiders own 11.01% of Cellular Biomedicine Group Inc shares according to the proxy statements.Institutional Investors own 8.36% of Cellular Biomedicine Group Inc shares.During last six month period, the net percent change held by insiders has seen a change of -12.99%.
Shares of Cellular Biomedicine Group Inc (CBMG) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.42 points or -2.26% at $18.19 with 18,250 shares getting traded. Post opening the session at $18.77, the shares hit an intraday low of $18.01 and an intraday high of $18.78 and the price vacillated in this range throughout the day. The company has a market cap of $218 M and the number of outstanding shares has been calculated to be 1,19,83,688 shares. The 52-week high of Cellular Biomedicine Group Inc is $41.7299 and the 52-week low is $10.44.
Cellular Biomedicine Group Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of new treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company’s technology includes two r cell platforms: Immune Cell therapy for treatment of a range of cancers using Tcm TCR clonality CAR-T and anti-PD-1 technologies human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases. It is focused on developing and marketing cell-based therapies based on its cellular platforms to treat serious chronic and degenerative diseases such as cancer orthopedic diseases (including osteoarthritis and tissue damage) various inflammatory diseases and metabolic diseases. It is conducting clinical studies for two stem cell based therapies to treat knee osteoarthritis (KOA) and Cartilage Defect (CD). It is conducting preclinical studies in Asthma and Chronic Obstructive Pulmonary Disease (COPD).